Streptococcal Pneumonia - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Streptococcal Pneumonia - Pipeline Review, H2 2016’, provides an overview of the Streptococcal Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Streptococcal Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Streptococcal Pneumonia

The report reviews pipeline therapeutics for Streptococcal Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Streptococcal Pneumonia therapeutics and enlists all their major and minor projects

The report assesses Streptococcal Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Streptococcal Pneumonia

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Streptococcal Pneumonia

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Streptococcal Pneumonia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abera Bioscience AB

Actelion Ltd

Affinivax Inc

Allergan Plc

Arsanis Inc

AstraZeneca Plc

Beijing Minhai Biotechnology Co Ltd

Biken Inc

ContraFect Corp

Crestone Inc

Daiichi ...

Abera Bioscience AB

Actelion Ltd

Affinivax Inc

Allergan Plc

Arsanis Inc

AstraZeneca Plc

Beijing Minhai Biotechnology Co Ltd

Biken Inc

ContraFect Corp

Crestone Inc

Daiichi Sankyo Company Ltd

FluGen Inc

GlaxoSmithKline Plc

ImmunoBiology Ltd

Indian Immunologicals Ltd

Integrated BioTherapeutics Inc

Lascco SA

LegoChem Biosciences Inc

Liquidia Technologies Inc

Merck & Co Inc

Mucosis BV

Panacea Biotec Ltd

Pfizer Inc

Prometheon Pharma LLC

Sanofi Pasteur SA

Serum Institute of India Ltd

Shionogi & Co Ltd

SK Chemicals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Valneva SE

Vaxxilon AG

Virometix AG

Wellstat Vaccines LLC

Wockhardt Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Streptococcal Pneumonia Overview 6

Therapeutics Development 7

Streptococcal Pneumonia - Therapeutics under Development by Companies 9 ...

Table of Contents

Table of Contents 2

Introduction 5

Streptococcal Pneumonia Overview 6

Therapeutics Development 7

Streptococcal Pneumonia - Therapeutics under Development by Companies 9

Streptococcal Pneumonia - Therapeutics under Investigation by Universities/Institutes 11

Streptococcal Pneumonia - Pipeline Products Glance 12

Streptococcal Pneumonia - Products under Development by Companies 16

Streptococcal Pneumonia - Products under Investigation by Universities/Institutes 19

Streptococcal Pneumonia - Companies Involved in Therapeutics Development 20

Streptococcal Pneumonia - Therapeutics Assessment 54

Drug Profiles 64

Streptococcal Pneumonia - Dormant Projects 136

Streptococcal Pneumonia - Discontinued Products 140

Streptococcal Pneumonia - Product Development Milestones 141

Appendix 152

List of Tables

List of Tables

Number of Products under Development for Streptococcal Pneumonia, H2 2016 14

Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, ...

List of Tables

Number of Products under Development for Streptococcal Pneumonia, H2 2016 14

Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Development, H2 2016 21

Comparative Analysis by Unknown Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Investigation by Universities/Institutes, H2 2016 26

Streptococcal Pneumonia - Pipeline by Abera Bioscience AB, H2 2016 27

Streptococcal Pneumonia - Pipeline by Actelion Ltd, H2 2016 28

Streptococcal Pneumonia - Pipeline by Affinivax Inc, H2 2016 29

Streptococcal Pneumonia - Pipeline by Allergan Plc, H2 2016 30

Streptococcal Pneumonia - Pipeline by Arsanis Inc, H2 2016 31

Streptococcal Pneumonia - Pipeline by AstraZeneca Plc, H2 2016 32

Streptococcal Pneumonia - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2016 33

Streptococcal Pneumonia - Pipeline by Biken Inc, H2 2016 34

Streptococcal Pneumonia - Pipeline by ContraFect Corp, H2 2016 35

Streptococcal Pneumonia - Pipeline by Crestone Inc, H2 2016 36

Streptococcal Pneumonia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 37

Streptococcal Pneumonia - Pipeline by FluGen Inc, H2 2016 38

Streptococcal Pneumonia - Pipeline by GlaxoSmithKline Plc, H2 2016 39

Streptococcal Pneumonia - Pipeline by ImmunoBiology Ltd, H2 2016 40

Streptococcal Pneumonia - Pipeline by Indian Immunologicals Ltd, H2 2016 41

Streptococcal Pneumonia - Pipeline by Integrated BioTherapeutics Inc, H2 2016 42

Streptococcal Pneumonia - Pipeline by Lascco SA, H2 2016 43

Streptococcal Pneumonia - Pipeline by LegoChem Biosciences Inc, H2 2016 44

Streptococcal Pneumonia - Pipeline by Liquidia Technologies Inc, H2 2016 45

Streptococcal Pneumonia - Pipeline by Merck & Co Inc, H2 2016 46

Streptococcal Pneumonia - Pipeline by Mucosis BV, H2 2016 47

Streptococcal Pneumonia - Pipeline by Panacea Biotec Ltd, H2 2016 48

Streptococcal Pneumonia - Pipeline by Pfizer Inc, H2 2016 49

Streptococcal Pneumonia - Pipeline by Prometheon Pharma LLC, H2 2016 50

Streptococcal Pneumonia - Pipeline by Sanofi Pasteur SA, H2 2016 51

Streptococcal Pneumonia - Pipeline by Serum Institute of India Ltd, H2 2016 52

Streptococcal Pneumonia - Pipeline by Shionogi & Co Ltd, H2 2016 53

Streptococcal Pneumonia - Pipeline by SK Chemicals Co Ltd, H2 2016 54

Streptococcal Pneumonia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 55

Streptococcal Pneumonia - Pipeline by Valneva SE, H2 2016 56

Streptococcal Pneumonia - Pipeline by Vaxxilon AG, H2 2016 57

Streptococcal Pneumonia - Pipeline by Virometix AG, H2 2016 58

Streptococcal Pneumonia - Pipeline by Wellstat Vaccines LLC, H2 2016 59

Streptococcal Pneumonia - Pipeline by Wockhardt Ltd, H2 2016 60

Assessment by Monotherapy Products, H2 2016 61

Assessment by Combination Products, H2 2016 62

Number of Products by Stage and Target, H2 2016 64

Number of Products by Stage and Mechanism of Action, H2 2016 66

Number of Products by Stage and Route of Administration, H2 2016 68

Number of Products by Stage and Molecule Type, H2 2016 70

Streptococcal Pneumonia - Dormant Projects, H2 2016 143

Streptococcal Pneumonia - Dormant Projects (Contd..1), H2 2016 144

Streptococcal Pneumonia - Dormant Projects (Contd..2), H2 2016 145

Streptococcal Pneumonia - Dormant Projects (Contd..3), H2 2016 146

Streptococcal Pneumonia - Discontinued Products, H2 2016 147

List of Figures

List of Figures

Number of Products under Development for Streptococcal Pneumonia, H2 2016 14

Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, ...

List of Figures

Number of Products under Development for Streptococcal Pneumonia, H2 2016 14

Number of Products under Development for Streptococcal Pneumonia - Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 18

Comparative Analysis by Late Stage Development, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 20

Comparative Analysis by Early Stage Products, H2 2016 21

Assessment by Monotherapy Products, H2 2016 61

Number of Products by Top 10 Targets, H2 2016 63

Number of Products by Stage and Top 10 Targets, H2 2016 63

Number of Products by Top 10 Mechanism of Actions, H2 2016 65

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 65

Number of Products by Routes of Administration, H2 2016 67

Number of Products by Stage and Routes of Administration, H2 2016 67

Number of Products by Molecule Types, H2 2016 69

Number of Products by Stage and Top 10 Molecule Types, H2 2016 69

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports